Case-Based Learning: Intermittent GI Bleeding With Negative Conventional Evaluation

Abstract

Intermittent gastrointestinal (GI) bleeding with negative findings on conventional evaluation presents a complex diagnostic and therapeutic challenge in clinical practice. Despite advancements in endoscopic and radiologic modalities, a subset of patients continue to experience obscure GI bleeding, leading to repeated hospitalizations, transfusion dependence, and increased morbidity. This review synthesizes the latest evidence-based approaches, focusing on epidemiology, pathophysiological mechanisms, risk assessment, clinical presentation, diagnostic strategies, management, recent innovations, and current guideline recommendations. Emphasis is placed on integrating case-based learning with practical implications to optimize patient care.

Introduction

Intermittent GI bleeding, defined as episodic hematochezia, melena, or occult blood loss with periods of clinical quiescence, poses significant diagnostic dilemmas, particularly when conventional upper and lower endoscopic evaluations are unrevealing. This scenario, often termed "obscure GI bleeding" (OGIB), necessitates a systematic, evidence-driven approach to identify underlying etiologies and guide management. The prevalence of OGIB is increasing with an aging population and the widespread use of antithrombotic agents. Understanding the nuances of its evaluation and treatment is critical for clinicians across gastroenterology, internal medicine, and emergency care settings.

Epidemiology / Disease Burden

Obscure GI bleeding accounts for approximately 5% of all GI hemorrhages. The incidence is estimated at 0.8–1.5 per 100,000 adults annually, with higher rates in elderly populations. The disease burden is substantial, with recurrent hospital admissions, resource utilization for repeated investigations, and significant impact on quality of life. Studies indicate that small bowel sources comprise 75% of OGIB cases, with vascular lesions, tumors, and inflammatory conditions predominating. The economic and psychosocial toll further underscores the need for efficient diagnostic and therapeutic algorithms.

Pathophysiology

The underlying mechanisms of intermittent GI bleeding with negative conventional evaluation are heterogeneous. Vascular lesions, such as angioectasias, arteriovenous malformations (AVMs), and Dieulafoy’s lesions, are leading causes, particularly in older adults. Tumors (benign and malignant), small bowel ulcers, Meckel’s diverticulum, and NSAID-induced enteropathy also contribute. The intermittent nature may reflect episodic bleeding from fragile lesions or transient ischemic insults. In some cases, bleeding may occur distal to the reach of standard endoscopes, or lesions may be missed due to their subtlety, location, or intermittent activity.

Risk Factors

Risk factors for intermittent OGIB include advanced age, chronic kidney disease, use of antiplatelet or anticoagulant medications, hereditary hemorrhagic telangiectasia, a history of GI malignancy, previous abdominal surgery, and chronic NSAID use. Systemic diseases such as cirrhosis and aortic stenosis (Heyde’s syndrome) are also implicated. Identifying risk factors is crucial for tailoring the diagnostic approach and anticipating potential etiologies.

Clinical Features

Patients may present with overt bleeding hematochezia or melena or occult blood loss manifesting as iron deficiency anemia, fatigue, or hemodynamic instability during acute episodes. The intermittent course often complicates clinical assessment, with normal findings between episodes. A thorough history focusing on bleeding characteristics, medication use, comorbidities, and family history is imperative. Physical examination may reveal signs of anemia, hemodynamic compromise, or stigmata of chronic disease.

Diagnosis

Initial evaluation includes upper and lower endoscopy, which are negative in OGIB cases. Repeat endoscopies may be considered if bleeding recurs within a short interval. Advanced diagnostic modalities are essential for further assessment:

- Video Capsule Endoscopy (VCE): First-line for small bowel evaluation, with a diagnostic yield of 50–70%.

- Device-Assisted Enteroscopy (DAE): Including single- and double-balloon enteroscopy, allows for direct visualization and intervention.

- Cross-Sectional Imaging: CT or MR enterography is valuable for identifying submucosal masses, vascular lesions, or inflammatory changes.

- Nuclear Medicine Scans: Technetium-labeled RBC scans can localize active bleeding at rates as low as 0.1–0.5 mL/min.

- Angiography: Useful for acute massive bleeding with potential for therapeutic embolization.

- Intraoperative Enteroscopy: Reserved for refractory cases after noninvasive modalities are exhausted.

Timing of diagnostic studies relative to bleeding episodes impacts yield. Multidisciplinary collaboration is often required.

Treatment & Management

Management strategies are etiology-specific and tailored to the severity and chronicity of bleeding:

- Endoscopic therapy: Argon plasma coagulation, clip application, or injection therapy for vascular or bleeding lesions.

- Medical management: Includes iron supplementation, hormonal therapy (estrogen-progesterone for angioectasia), and somatostatin analogues for refractory cases.

- Radiologic intervention: Angioembolization for acute, ongoing bleeding identified by angiography.

- Surgical intervention: Segmental resection for localized, refractory bleeding or neoplastic lesions.

- Supportive care: Transfusion, hemodynamic monitoring, and correction of coagulopathies.

Multidisciplinary input from gastroenterology, radiology, and surgery is critical for optimal outcomes.

Recent Advances / Emerging Therapies

Technological advances have revolutionized the diagnostic approach to OGIB. High-resolution VCE, deep enteroscopy techniques, and AI-assisted image analysis have improved lesion detection and characterization. Novel endoscopic therapies, such as radiofrequency ablation and over-the-scope clips, offer promising results in managing refractory vascular lesions. Pharmacologic research is exploring targeted therapies for vascular and neoplastic causes. Personalized medicine approaches, integrating genetic risk profiling, are on the horizon for recurrent, unexplained cases.

Guideline Recommendations

Major societies, including the American College of Gastroenterology (ACG) and European Society of Gastrointestinal Endoscopy (ESGE), recommend VCE as the initial diagnostic step after negative conventional endoscopy for OGIB. DAE is indicated for lesions identified by VCE or persistent bleeding. Repeat standard endoscopy is considered if symptoms recur within two weeks. Interdisciplinary care and individualized patient assessment are emphasized. Guidelines advocate for stepwise escalation, judicious use of transfusions, and consideration of patient comorbidities in decision-making.

Conclusion

Intermittent GI bleeding with negative conventional evaluation remains a diagnostic and therapeutic challenge, requiring a systematic, multidisciplinary approach grounded in current evidence and guidelines. Advances in endoscopic and imaging techniques have significantly enhanced lesion detection and management, yet a high index of suspicion and individualized care remain paramount. Ongoing research and emerging technologies promise further improvements in diagnostic yield and patient outcomes. For clinicians, mastery of the latest evidence-based strategies is essential to optimize care for this complex patient population.